Skip to content

Enhanced Recovery After Surgery in Hysterectomy Patients

Effectiveness of Enhanced Recovery After Surgery (ERAS) Protocols in Hysterectomy Patients. A Prospective,Randomized Controlled Clinical Trial.

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07564063
Acronym
ERAS
Enrollment
78
Registered
2026-05-04
Start date
2026-06-01
Completion date
2027-01-01
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Enhanced Recovery After Surgery (ERAS) Protocol

Brief summary

This prospective randomized controlled clinical trial aims to evaluate the effectiveness of Enhanced Recovery After Surgery (ERAS) protocols in patients undergoing elective hysterectomy. ERAS is an evidence-based perioperative approach designed to reduce surgical stress, accelerate recovery, and improve clinical outcomes. Participants will be randomized to receive either ERAS-based care or conventional perioperative management. The study will assess whether ERAS implementation reduces hospital stay and improves postoperative recovery without increasing complications.

Detailed description

Enhanced Recovery After Surgery (ERAS) protocols are structured, multidisciplinary perioperative care pathways developed to optimize surgical outcomes by minimizing physiological stress and promoting early recovery. These protocols include preoperative counseling, shortened fasting with carbohydrate loading, opioid-sparing anesthesia, early feeding, and early mobilization. Hysterectomy remains one of the most common gynecological procedures worldwide and is often associated with prolonged hospital stay and postoperative morbidity, particularly in resource-limited settings. While international evidence supports the benefits of ERAS in improving outcomes such as reduced length of hospital stay, improved pain control, and decreased complications, there is a need for locally generated data to validate its effectiveness in Egyptian tertiary healthcare settings. This study will be conducted at Kasr Al-Ainy Hospital, Cairo University, and will include women undergoing elective hysterectomy for benign or early-stage malignant gynecological conditions. Participants will be randomly assigned to either the ERAS group or the conventional care group. Outcomes will be assessed during hospitalization and up to 30 days postoperatively.

Interventions

DRUGdextrose (5%)

IV dextrose infusion (5%) 500 ml once ,2-3 hours before anesthesia

Reduced fasting Early oral feeding Early mobilization

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Women aged 18-70 years. * Undergoing elective total hysterectomy for benign or early stage malignant gynacological conditions . * ASA ( American Society of Anesthesiologists ) physical status I-II. * Able to provide informed consent.

Exclusion criteria

* Emergency hysterectomy * Advanced malignant requiring extensive debulking * Known bowel disease or previous bowel surgery ( crohn's disease , bowel obstruction ) * Significant cognitive impairment or psychiatric illness * Inability to follow ERAS protocol (e.g., cognitive impairment) * Refusal to participate

Design outcomes

Primary

MeasureTime frameDescription
length of hospital stay (LOS)From day of surgery up to 7 postoperative daysTime from completion of surgery to hospital discharge readiness, measured in days.

Secondary

MeasureTime frameDescription
postoperative pain scoreAt 12 and 24 hours postoperativelyPostoperative pain intensity measured using the Visual Analog Scale (VAS), a 10-cm scale ranging from 0 (no pain) to 10 (worst imaginable pain).
time to first bowel movementUp to 5 postoperative daysthe interval (in hours) from completion of surgery to the first documented passage of stool."

Countries

Egypt

Contacts

CONTACTEhab H Sorour, MD
dr.ehabsorour@gmail.com+201112496821
CONTACTMohamed E El Mahy, MD
mohammed.elmahy@kasralainy.edu.eg+201111831716
PRINCIPAL_INVESTIGATOREhab H Sorour, MD

Cairo University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 5, 2026